Loading...
•
Dec 31, 2024
Allurion Q4 2024 Earnings Report
Allurion reported its Q4 2024 results, showing decreased revenue and gross margin due to temporary market challenges and restructuring efforts.
Key Takeaways
The company reported Q4 2024 revenue of $5.6 million, down from $8.2 million in the prior year. Gross margin declined to 45% due to lower production volumes and inventory adjustments. Operating expenses were reduced significantly, contributing to a lower net loss compared to previous quarters.
Q4 2024 revenue was $5.6 million, down from $8.2 million in Q4 2023.
Gross profit margin decreased to 45%, impacted by lower volumes and inventory adjustments.
Operating expenses decreased by 39% year-over-year, reflecting restructuring efforts.
Net loss for Q4 2024 totaled $20.6 million compared to $19.2 million in Q4 2023.
Forward Guidance
Allurion expects $30 million in revenue for 2025 with further reductions in operating expenses and continued commercial expansion, particularly after resuming sales in France.
Positive Outlook
- Resumption of sales in France as of February 2025.
- Launch of next-generation Allurion Balloon with improved features.
- Positive topline results from the AUDACITY FDA clinical trial.
- Expected gross margin improvement as inventory normalizes.
- Recent financings provide runway through expected FDA approval.
Challenges Ahead
- Revenue decline driven by temporary suspension in France.
- Lower production volumes impacting cost absorption.
- Significant restructuring charges incurred in Q4 2024.
- Continued macroeconomic headwinds affecting re-orders.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...